Article Text

Download PDFPDF
Can we extend the indication for sentinel node biopsy in vulvar cancer? A nationwide feasibility study from Sweden
  1. Diana Zach1,
  2. Paivi Kannisto2,
  3. Katja Stenström Bohlin3,
  4. Louise Moberg2 and
  5. Preben Kjölhede4
  1. 1 Division for Obstetrics and Gynecology, Karolinska University Hospital, Stockholm, Sweden
  2. 2 Obstetrics and Gynecology, Clinical Sciences, Lund, Sweden
  3. 3 Department of Obstetrics and Gynecology, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden
  4. 4 Obstetrics and Gynecology, Linkopings Universitet Institutionen for klinisk och experimentell medicin, Linkoping, Sweden
  1. Correspondence to Dr Diana Zach, Division for Obstetrics and Gynecology, Karolinska University Hospital, 171 76 Solna, Sweden; diana.zach{at}sll.se

Abstract

Background In squamous cell vulvar cancer, sentinel node biopsy is accepted as standard treatment in well-defined patient groups and has reduced surgical morbidity considerably. Currently, due to the lack of evidence, it cannot be offered to patients with tumors of 4 cm diameter or greater or with multifocal tumors, or in local recurrences.

Primary objective This study is primarily a pilot and feasibility trial, aiming to evaluate if the prerequisites concerning detection rate and negative predictive value are satisfactory before the implementation of a multinational trial.

Study hypothesis Sentinel node biopsy has an acceptable negative predictive value and detection rate in the study cohort.

Trial design This study is planned as a prospective, national, multicenter interventional trial. Participating patients will undergo a sentinel node biopsy in addition to an inguinofemoral lymphadenectomy.

Inclusion and exclusion criteria Inclusion criteria: for women in group 1, a primary tumor ≥4 cm in diameter; in group 2, a multifocal primary tumor; in group 3, a local recurrence without previous inguinofemoral lymphadenectomy or radiation to the groins; in group 4, a local recurrence, with previous inguinofemoral lymphadenectomy and/or radiation to the groins.

Primary endpoint The primary endpoints are the detection rate and the negative predictive value of the sentinel node procedure.

Sample size In each of the four study arms, recruitment of 20–30 patients is planned.

Estimated dates for completing recruitment and presenting results Recruitment will take place between November 2019 and October 2021. Results will be available in December 2021.

Trial registration The trial is registered at “ClinicalTrials.gov” (ID: NCT04147780).

  • vulvar and vaginal cancer
  • sentinel lymph node
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Conception and study design: D Zach, P Kjölhede, L Moberg, K Stenström Bohlin, P Kannisto; Statistical calculations, data interpretation: D Zach, P Kjölhede; Manuscript writing: D Zach, P Kjölhede; Manuscript editing and reviewing: D Zach, P Kjölhede, K Stenström Bohlin, L Moberg, P Kannisto; Final approval of manuscript: D Zach, P Kjölhede, K Stenström Bohlin, L Moberg, P Kannisto.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.